Methyldopa: Drug Class and Mechanism of Action
Methyldopa is a centrally acting alpha-2 adrenergic agonist that lowers blood pressure through central sympatholytic action by stimulating alpha-2 adrenergic receptors in the brainstem. 1, 2
Drug Classification
Methyldopa belongs to the class of central alpha-2 agonists and other centrally acting antihypertensive drugs 3, 4, 5. It is specifically categorized alongside other centrally acting agents like clonidine and guanfacine, though its mechanism differs slightly from direct alpha-2 agonists.
Mechanism of Action
The antihypertensive effect operates through a multi-step process:
Central Mechanism (Primary)
- Methyldopa is metabolized to alpha-methylnorepinephrine in the central nervous system 2
- This metabolite stimulates central inhibitory alpha-2 adrenergic receptors in the pontomedullary region of the brainstem 1
- This stimulation activates inhibitory neurons that reduce peripheral sympathetic tone, resulting in decreased blood pressure and heart rate 6, 7
Additional Mechanisms
The drug also works through:
- False neurotransmission: Alpha-methylnorepinephrine acts as a false neurotransmitter, replacing norepinephrine at nerve terminals 2, 8
- Reduction of plasma renin activity through peripheral mechanisms 2, 9
- Depletion of tissue catecholamines (serotonin, dopamine, norepinephrine, epinephrine) 2
Clinical Pharmacology
Methyldopa requires enzymatic conversion by aromatic-amino-acid decarboxylase to become active 2. The drug:
- Reaches maximum blood pressure reduction 4-6 hours after oral dosing 2
- Has a plasma half-life of 105 minutes 2
- Does not directly affect cardiac function or reduce glomerular filtration rate 2
- Produces smooth blood pressure control over 12-24 hours once effective dosing is achieved 2
Important Clinical Context
While methyldopa was commonly used in the 1970s-80s, it has largely fallen out of favor in high-income countries due to its side effect profile (peripheral edema, dry mouth, lightheadedness, drowsiness, mood effects) 1. However, it remains relevant because:
- It is the only antihypertensive with long-term safety data on infant outcomes, making it acceptable for pregnancy 1
- Beta-blockers and calcium channel blockers are more effective than methyldopa for preventing severe hypertension in pregnancy 1
- It is still widely used in low- and middle-income countries due to low cost 1
The usual dosing range is 250-1000 mg daily in 2 divided doses 3, 4, 5.